NASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis $0.73 -0.05 (-5.93%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.73 +0.00 (+0.04%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AEON Biopharma Stock (NASDAQ:AEON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AEON Biopharma alerts:Sign Up Key Stats Today's Range$0.73▼$0.7850-Day Range$0.66▼$0.8652-Week Range$0.38▼$115.57Volume55,781 shsAverage Volume1.58 million shsMarket Capitalization$8.52 millionP/E Ratio4.07Dividend YieldN/APrice Target$360.00Consensus RatingBuy Company Overview AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California. Read More AEON Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreAEON MarketRank™: AEON Biopharma scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAEON Biopharma has received no research coverage in the past 90 days.Read more about AEON Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AEON Biopharma is 4.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.88.Price to Earnings Ratio vs. SectorThe P/E ratio of AEON Biopharma is 4.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.27. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.71% of the float of AEON Biopharma has been sold short.Short Interest Ratio / Days to CoverAEON Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AEON Biopharma has recently decreased by 9.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.71% of the float of AEON Biopharma has been sold short.Short Interest Ratio / Days to CoverAEON Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AEON Biopharma has recently decreased by 9.13%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 4 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows2 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.86% of the stock of AEON Biopharma is held by insiders.Percentage Held by InstitutionsOnly 22.78% of the stock of AEON Biopharma is held by institutions.Read more about AEON Biopharma's insider trading history. Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AEON Stock News HeadlinesAeon Biopharma Advances Biosimilar DevelopmentAugust 13, 2025 | msn.comAEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | globenewswire.comBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.August 30 at 2:00 AM | Altimetry (Ad)AEON Biopharma, Inc. (AEON) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comHexagon launches AEON, a humanoid built for industryJune 17, 2025 | prnewswire.comAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711May 23, 2025 | globenewswire.comAEON Biopharma to Present Corporate Overview at Aegis Capital Corp. 2025 Virtual ConferenceMay 21, 2025 | nasdaq.comAEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025May 19, 2025 | globenewswire.comSee More Headlines AEON Stock Analysis - Frequently Asked Questions How have AEON shares performed this year? AEON Biopharma's stock was trading at $38.88 at the beginning of the year. Since then, AEON stock has decreased by 98.1% and is now trading at $0.7317. When did AEON Biopharma's stock split? AEON Biopharma shares reverse split before market open on Wednesday, February 26th 2025.The 1-72 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AEON Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE). Company Calendar Today8/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CIK1837607 Webwww.aeonbiopharma.com Phone754-220-9229FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for AEON Biopharma$360.00 High Price Target$360.00 Low Price Target$360.00 Potential Upside/Downside+49,100.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($6.08) Trailing P/E Ratio4.07 Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.63 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-994.63% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.18Miscellaneous Outstanding Shares11,644,000Free Float74,373,000Market Cap$8.52 million OptionableNot Optionable Beta0.71 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AEON) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
